Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Active Ankylosing Spondylitis
NCT01583374Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2012
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of apremilast in ankylosing spondylitis (AS), sponsored by Amgen. Started May 2012; status: completed.
02
Drugs
apremilast
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT01583374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01583374.